The impaired disposition of probe drugs is due to both liver and kidney dysfunctions in CCl 4-model rats

Environmental Toxicology and Pharmacology

Volumn 33, Issue 3, 2012, Pages 453-458

  Zhang, Yan ^a   Jia, Yanyan ^b   Yang, Mengmeng ^a   Yang, Peng ^a   Tian, Yun ^b   Xiao, Aiping ^a   Wen, Aidong ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carbon tetrachloride; Disposition; Model rats; Probe drugs; Sprague Dawley rats

Indexed keywords

CYTOCHROME P450 1A2; GLUCURONOSYLTRANSFERASE 1A6; MESSENGER RNA; PARACETAMOL; PHENACETIN; SULFOTRANSFERASE 1A1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOCHROME P4501A2 GENE; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; ENZYME MECHANISM; GENE; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; RAT; SULFOTRANSFERASE 1A1 GENE; UDP GLUCOSYLTRANSFERASE 1A6 GENE; URINARY EXCRETION;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; ARYLSULFOTRANSFERASE; CARBON TETRACHLORIDE POISONING; CYTOCHROMES; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; GLUCURONOSYLTRANSFERASE; KIDNEY DISEASES; MALE; PHENACETIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

RATTUS;

EID: 84862822033     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2012.01.002     Document Type: Article

References (21)

1. Bastien M.C., Leblond F., Pichette V., Villeneuve J.P. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can. J. Physiol. Pharmacol. 2000, 78:912-919.
2. Bhadauria M., Nirala S.K., Shrivastava S., Sharma A., Johri S., Chandan B.K., Singh B., Saxena A.K., Shukla S. Emodin reverses CCl induced hepatic cytochrome P450 (CYP) enzymatic and ultrastructural changes: the in vivo evidence. Hepatol. Res. 2009, 39:290-300.
3. Bhadauria M., Nirala S.K., Shukla S. Propolis protects CYP 2E1 enzymatic activity and oxidative stress induced by carbon tetrachloride. Mol. Cell Biochem. 2007, 302:215-224.
4. Fujii T., Fuchs B.C., Yamada S., Lauwers G.Y., Kulu Y., Goodwin J.M., Lanuti M., Tanabe K.K. Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010, 10:79.
5. Fukao T., Hosono T., Misawa S., Seki T., Ariga T. The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride. Food Chem. Toxicol. 2004, 42:743-749.
6. Gassó M., Rubio M., Varela G., Cabré M., Caballería J., Alonso E., Deulofem R., Camps J., Giménez A., Pajares M., Parés A., Mato J.M., Rodés J. Effect of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J. Hepatol. 1996, 25:200-205.
7. Gorla N., de Ferreyra E.C., Villarruel M.C., de Fenos O.M., Castro J.A. Studies on the mechanism of glutathione prevention of carbon tetrachloride-induced liver injury. Br. J. Exp. Pathol. 1983, 64:388-395.
8. Jiang Y., Liu J., Waalkes M., Kang Y.J. Changes in the gene expression associated with carbon tetrachloride-induced liver fibrosis persist after cessation of dosing in mice. Toxicol. Sci. 2004, 79:404-410.
9. Jurica J., Konecny J., Zahradnikova L.Z., Tomandl J. Simultaneous HPLC determination of tolbutamide, phenacetin and their metabolites as markers of cytochromes 1A2 and 2C6/11 in rat liver perfusate. J. Pharm. Biomed. Anal. 2010, 52:557-564.
10. 4-treated rats using in vivo CYP1A2 and CYP3A2 contents assessed with the PKCYP test. Drug Metab. Pharmacokinet. 2005, 20:168-176.
11. Mark A.L., Sun Z., Warren D.S., Lonze B.E., Knabel M.K., Melville W.G., Locke J.E., Montgomery R.A., Cameron A.M. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann. Surg. 2010, 252:591-596.
12. Manibusan M.K., Odin M., Eastmond D.A. Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C: Environ. Carcinog. Ecotoxicol. Rev. 2007, 25:185-209.
13. O'Neil W.M., Pezzullo J.C., Di Girolamo A., Tsoukas C.M., Wainer I.W. Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS. Br. J. Clin. Pharmacol. 1999, 48:811-818.
14. Ohnuma T., Anan E., Hoashi R., Takeda Y., Nishiyama T., Ogura K., Hiratsuka A. Dietary diacetylene falcarindiol induces phase 2 drug-metabolizing enzymes and blocks carbon tetrachloride-induced hepatotoxicity in mice through suppression of lipid peroxidation. Biol. Pharm. Bull. 2011, 34:371-378.
15. Qu Z.Q., Li X.D., Liu H.L., He P., Zhang X., Wu M.C. Impaired clearance of phenacetin in hepatic cirrhosis and fibrosis. Int. J. Clin. Pharmacol. Ther. 2007, 45:55-62.
16. Sugiyama T., Nagata J., Yamagishi A., Endoh K., Saito M., Yamada K., Yamada S., Umegaki K. Selective protection of curcumin against carbon tetrachloride-induced inactivation of hepatic cytochrome P450 isozymes in rats. Life Sci. 2006, 78:2188-2193.
17. Showkat A.G., Ehtishamul H., Abid H., Yasrib Q., Zahid M., Bilal A.Z., Akbar M., Mohmmad A.Z. Carbon tetrachloride induced kidney and lung tissue damages and antioxidant activities of the aqueous rhizome extract of Podophyllum hexa. BMC Complem. Altern. Med. 2011, 11:17-27.
18. 4 intoxication. Am. J. Pathol. 1968, 53:769-789.
19. Yim H.K., Jung Y.S., Kim S.Y., Kim Y.C. Contrasting changes in phase I and phase II metabolism of acetaminophen in male mice pretreated with carbon tetrachloride. Basic Clin. Pharmacol. Toxicol. 2006, 98:225-230.
20. Yokogawa K., Watanabe M., Takeshita H., Nomura M., Mano Y., Miyamoto K. Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride. Int. J. Pharm. 2004, 269:479-489.
21. Zhang Y., Jia Y., Liu X., Liu L., Wang Q., Wen A. The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2010, 65:347-352.